ILMN Stock — Illumina, Inc.

Illumina, Inc. (ILMN)

Updated October 16, 2026.

ILMN is a Stock. Total return is 1278.0% over the past 26.2 years, 522.8 points ahead of SPY at 755.2%.

Illumina develops sequencing and array-based instruments, consumables, and services for genetic and genomic analysis, serving research institutions, diagnostic laboratories, pharmaceutical companies, and consumer genomics firms worldwide. The company does not currently pay distributions. Illumina operates as an operating company in the healthcare sector, generating revenue from the sale of sequencing instruments, reagents, and related services rather than from investment income.

ILMN performance versus SPY

Price and return data through 2026-10-16.

Total return is 1278.0% over the past 26.2 years, 522.8 points ahead of SPY at 755.2%. Over the past year its total return — price change plus distributions reinvested — is 173.7%. Its deepest 1-year drawdown was 25.7%.

ILMN key facts

Asset type

Stock

Asset class

Equity

Inception date

07/28/2000

Distribution frequency

None

Last close

$262.54 (as of 2026-10-16)

Market cap

$39,643,540,000

Average volume

2488968.0

Beta

1.416

Payout ratio

0.0%

P/E ratio

48.89

Forward P/E

40.3226

EPS

$5.37

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ILMN risks and drawbacks

The deepest 1-year drawdown on record here is 25.7%.

Who may consider ILMN — and who may not

It is a weaker fit for investors who need monthly cash flow (ILMN does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on ILMN

• ETFs holding ILMN
• All tickers starting with I

Tagged: Healthcare.

Frequently asked questions